Therapeutic Strategies for MASLD Based on Pathogenic Driver
Current evidence does not support tailoring MASLD therapy based on specific pathogenic drivers (adipose-driven, hepatic insulin resistance, or PNPLA3 variants); instead, all patients should receive the same foundational treatment—weight loss of 7–10% through Mediterranean diet and ≥150 min/week exercise, with resmetirom for non-cirrhotic MASH with fibrosis ≥F2, and GLP-1 agonists or tirzepatide for comorbid diabetes/obesity—because no precision-medicine approach has been validated in clinical trials. 1, 2
Why Pathogenic-Driver Stratification Is Not Yet Clinically Actionable
The 2024 EASL-EASD-EASO guidelines explicitly identify the need to "understand individual susceptibility and determinants of fibrosis progression" and to "develop effective pharmacological treatments" tailored to pathophysiology as a key research gap, confirming that precision medicine for MASLD does not yet exist. 1
Although PNPLA3 148M is the strongest genetic determinant of MASH and is being targeted in phase 2b trials with hepatic silencing approaches, no PNPLA3-directed therapy is approved or recommended in current guidelines; these agents remain investigational. 3, 4
Heterogeneity in MASLD pathogenesis—including adipose dysfunction, hepatic insulin resistance, and genetic variants—is well-documented, yet this heterogeneity has not translated into differential treatment recommendations because response to therapy (weight loss, resmetirom, GLP-1 agonists) does not reliably correlate with the predominant driver. 5
Universal Foundational Therapy (All Pathogenic Drivers)
Weight Loss and Lifestyle
Achieve 7–10% total body-weight reduction to resolve steatohepatitis and regress fibrosis; even 5% loss reduces hepatic steatosis. 1, 2, 6
Adopt a Mediterranean dietary pattern rich in vegetables, fruits, olive oil, nuts, legumes, and unprocessed fish/poultry while eliminating sugar-sweetened beverages and ultra-processed foods. 1, 2, 6
Prescribe ≥150 min/week of moderate-intensity or ≥75 min/week of vigorous-intensity aerobic exercise. 1, 2, 6
Advise complete alcohol avoidance, especially in advanced fibrosis or cirrhosis. 1, 2
Pharmacologic Therapy (Non-Cirrhotic MASH with Fibrosis ≥F2)
MASH-Targeted Agent
Resmetirom is the first FDA-approved disease-modifying therapy for non-cirrhotic MASH with fibrosis stage F2–F3; phase III trials demonstrated superior histologic resolution of steatohepatitis and fibrosis regression with acceptable safety. 1, 2, 7
Resmetirom is contraindicated in decompensated cirrhosis (F4); no MASH-targeted pharmacotherapy is recommended for cirrhotic patients. 1, 2
Metabolic Comorbidity Management
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) or the GLP-1/GIP co-agonist tirzepatide are first-line agents for patients with comorbid type 2 diabetes or obesity; semaglutide has FDA conditional approval for MASH with F2–F3 fibrosis, achieving MASH resolution without fibrosis worsening in 59% versus 17% with placebo. 1, 2, 6, 8
SGLT2 inhibitors (empagliflozin, dapagliflozin) are alternative glucose-lowering agents that modestly reduce liver fat and ALT. 1, 2, 8
Continue metformin in compensated cirrhosis (eGFR >30 mL/min) because discontinuation may increase mortality, although metformin alone does not improve histology. 2, 6
Pioglitazone improves adipose-tissue function and liver histology through insulin-sensitizing mechanisms independent of weight loss, but it is not recommended as MASH-targeted therapy due to lack of robust phase III efficacy data and causes modest weight gain (2–5 kg). 1, 6
Bariatric Surgery
Offer bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) to patients with BMI ≥40 kg/m² or BMI ≥35 kg/m² with metabolic comorbidities who have failed lifestyle and pharmacologic measures; surgery induces long-term liver benefit, diabetes remission, and improved cardiometabolic risk. 1, 2, 6
In compensated cirrhosis, bariatric surgery may be considered after multidisciplinary assessment of portal hypertension and surgical risk. 1, 2
Special Considerations by Pathogenic Context
Adipose-Driven Disease (Obesity-Predominant)
Weight-loss interventions (lifestyle, GLP-1 agonists, tirzepatide, bariatric surgery) are most effective when adipose dysfunction is the primary driver, yet these same interventions remain the cornerstone for all MASLD patients regardless of driver. 2, 9, 5
Non-incretin weight-loss agents (orlistat, phentermine-topiramate, naltrexone-bupropion) are not recommended due to insufficient efficacy data in MASH. 1, 2
Primary Hepatic Insulin Resistance
Pioglitazone (a PPAR-γ agonist) directly improves hepatic insulin sensitivity and may benefit patients with primary hepatic insulin resistance, but it is not recommended as MASH-targeted therapy and causes weight gain; use only when modest weight gain is acceptable or when comorbid diabetes requires glucose control. 1, 6, 8
GLP-1 agonists and tirzepatide improve hepatic insulin sensitivity through weight-loss-dependent and weight-loss-independent mechanisms, making them suitable for hepatic insulin resistance. 2, 8, 5
PNPLA3 Genetic Predisposition
PNPLA3 148M carriers have the highest genetic risk for MASH and fibrosis progression, yet no approved therapy specifically targets this variant; hepatic silencing of PNPLA3 is in phase 2b trials but remains investigational. 3, 4
PNPLA3 148M carriers respond to the same foundational therapies (weight loss, resmetirom, GLP-1 agonists) as non-carriers, so current management does not differ by genotype. 3, 5
Weight loss may be less effective in PNPLA3 148M homozygotes because the genetic variant persists regardless of weight change, but weight reduction still improves metabolic comorbidities and should be pursued. 3, 5
Management in Cirrhosis (All Drivers)
No MASH-targeted pharmacotherapy is recommended for cirrhotic patients; management focuses on metabolic optimization, nutritional support, HCC surveillance, and transplant evaluation. 1, 2
Provide a high-protein diet (1.2–1.5 g/kg body weight/day) with total calories ≥35 kcal/kg/day and a late-evening snack to preserve muscle mass in sarcopenic or decompensated patients. 1, 2
In compensated cirrhosis with obesity, a moderate weight-loss plan emphasizing adequate protein intake and physical activity is acceptable to avoid sarcopenia. 1, 2
Monitoring and Multidisciplinary Care
Use FIB-4 score and transient elastography to stage fibrosis; fibrosis ≥F2 identifies patients at risk for liver-related outcomes and determines eligibility for resmetirom. 1, 2, 6
Repeat non-invasive fibrosis tests (FIB-4, elastography) annually for F2/F3 and every 2–3 years for F0/F1 to monitor progression; recognize that these tests have limited ability to assess treatment response. 1, 2
Implement a multidisciplinary team (hepatology, endocrinology, nutrition, cardiology, surgery) to address the intertwined liver disease, diabetes, obesity, and cardiovascular risk. 1, 2, 6
Common Pitfalls
Do not withhold statins solely because of liver disease; they are safe, cardioprotective, and reduce HCC risk by 37%. 2
Do not discontinue metformin in compensated cirrhosis with type 2 diabetes, as withdrawal may increase mortality. 2, 6
Avoid metformin in decompensated cirrhosis or when eGFR <30 mL/min due to lactic acidosis risk. 2, 6
Do not prescribe resmetirom in cirrhotic patients (F4). 1, 2
Do not genotype for PNPLA3 to guide therapy selection, as no genotype-directed treatment is validated or recommended. 3, 5